Humanized antibodies against monocyte chemotactic proteins
View Patent ↗The invention provides humanized antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
1. An isolated nucleic acid molecule encoding a humanized immunoglobulin or antigen-binding fragment thereof comprising a) heavy chain complementarity determining regions as set forth in SEQ ID NO:29, SEQ ID NO:30, and SEQ ID NO:31, wherein the heavy chain further comprises at least one variable region framework residue from the monoclonal antibody 11K2 heavy chain set forth as SEQ ID NO: 27, wherein the residue is selected from the group consisting of L27, I29, and T73 (Kabat numbering convention) and b) light chain complementarity determining regions as set forth in SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34, wherein the light chain further comprises at least one variable region framework residue from the monoclonal antibody 11K2 light chain set forth as SEQ ID NO: 28, wherein the residue is selected from the group consisting of S49 and Y71 (Kabat numbering convention), wherein the remainder of the immunoglobulin or antigen-binding fragment is from a human immunoglobulin, wherein the immunoglobulin or antigen-binding fragment binds to MCP-1, MCP-2, or MCP-3.
2. An isolated nucleic acid molecule encoding a humanized immunoglobulin or antigen-binding fragment thereof comprising a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 47, and SEQ ID NO:48, and b) a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:49, and SEQ ID NO:50, wherein the immunoglobulin or antigen-binding fragment binds to MCP-1, MCP-2, or MCP-3.
3. An isolated vector comprising the nucleic acid molecule of claim 1 .
4. An isolated host cell comprising the nucleic acid molecule of claim 1 .
5. The host cell of claim 4 , wherein the cell is mammalian.
6. The host cell of claim 4 , wherein the cell is bacterial.
7. The nucleic acid of claim 1 , wherein the heavy chain further comprises variable region framework residues L27, I29, and T73 (Kabat numbering convention) from the monoclonal antibody 11K2 heavy chain as set forth in SEQ ID NO:27.
8. The nucleic acid of claim 1 , wherein the light chain further comprises variable region framework residues S49 and Y71 (Kabat numbering convention) from the monoclonal antibody 11K2 light chain as set forth in SEQ ID NO:28.
9. The nucleic acid of claim 1 , wherein the heavy chain comprises variable region framework residues L27, I29, and T73 (Kabat numbering convention), and the light chain comprises variable region framework residues S49 and Y71 (Kabat numbering convention).